Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Skinvisible Inc. (SKVI : OTC)

• Company Description    SKINVISIBLE PHARMACEUTICALS Inc., a wholly owned subsidiary of Skinvisible Inc., is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the patent. Number of Employees: 2

• Price / Volume Information    Yesterday's Closing Price: $0.49 Daily Weekly Monthly 20 Day Moving Average: 11,396 shares Shares Outstanding: 5.40 (millions) Market Capitalization: $2.65 (millions) Beta: 1.04 52 Week High: $0.90 52 Week Low: $0.08 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -24.03% -26.02% 12 Week 204.16% 191.55% Year To Date 45.40% 27.09%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 6320 S SANDHILL ROAD SUITE 10 - LAS VEGAS,NV 89120 USA ph: 702-433-7154 fax: 702-433-7192 ir@skinvisible.com http://www.skinvisible.com

• General Corporate Information    Officers Terry Howlett - Chief Executive Officer;President and Chief Financ David St. James - Director Greg McCartney - Director - - - - - - Peer Information Skinvisible Inc. (GSAC) Skinvisible Inc. (CASI) Skinvisible Inc. (ALCD.) Skinvisible Inc. (OMNN) Skinvisible Inc. (CGPI.) Skinvisible Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 830703203 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/18/25 Share - Related Items Shares Outstanding: 5.40 Most Recent Split Date: 1.00 (0.02:1) Beta: 1.04 Market Capitalization: $2.65 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/18/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 132.39 EPS Growth vs. Year Ago Period: 28.57% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: 0.00% ROE 09/30/25 - - 06/30/25 - - 03/31/25 - - ROA 09/30/25 - - 06/30/25 - -351.46 03/31/25 - -359.02 Current Ratio 09/30/25 - - 06/30/25 - 0.01 03/31/25 - 0.01 Quick Ratio 09/30/25 - - 06/30/25 - 0.01 03/31/25 - 0.01 Operating Margin 09/30/25 - - 06/30/25 - -2,635.00 03/31/25 - -2,780.00 Net Margin 09/30/25 - - 06/30/25 - -2,635.00 03/31/25 - -2,780.00 Pre-Tax Margin 09/30/25 - - 06/30/25 - -2,640.00 03/31/25 - -2,785.00 Book Value 09/30/25 - - 06/30/25 - -1.80 03/31/25 - -1.75 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Capital 09/30/25 - - 06/30/25 - - 03/31/25 - -

Powered by Zacks Investment Research ©